JPWO2020122034A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020122034A5
JPWO2020122034A5 JP2020560106A JP2020560106A JPWO2020122034A5 JP WO2020122034 A5 JPWO2020122034 A5 JP WO2020122034A5 JP 2020560106 A JP2020560106 A JP 2020560106A JP 2020560106 A JP2020560106 A JP 2020560106A JP WO2020122034 A5 JPWO2020122034 A5 JP WO2020122034A5
Authority
JP
Japan
Prior art keywords
antibody
pharmaceutical composition
amino acid
seq
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020560106A
Other languages
English (en)
Japanese (ja)
Other versions
JP7608164B2 (ja
JPWO2020122034A1 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2019/048171 external-priority patent/WO2020122034A1/ja
Publication of JPWO2020122034A1 publication Critical patent/JPWO2020122034A1/ja
Publication of JPWO2020122034A5 publication Critical patent/JPWO2020122034A5/ja
Priority to JP2024221344A priority Critical patent/JP2025041725A/ja
Application granted granted Critical
Publication of JP7608164B2 publication Critical patent/JP7608164B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020560106A 2018-12-11 2019-12-10 抗体-薬物コンジュゲートとparp阻害剤の組み合わせ Active JP7608164B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024221344A JP2025041725A (ja) 2018-12-11 2024-12-18 抗体-薬物コンジュゲートとparp阻害剤の組み合わせ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018231948 2018-12-11
JP2018231948 2018-12-11
PCT/JP2019/048171 WO2020122034A1 (ja) 2018-12-11 2019-12-10 抗体-薬物コンジュゲートとparp阻害剤の組み合わせ

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024221344A Division JP2025041725A (ja) 2018-12-11 2024-12-18 抗体-薬物コンジュゲートとparp阻害剤の組み合わせ

Publications (3)

Publication Number Publication Date
JPWO2020122034A1 JPWO2020122034A1 (ja) 2021-10-28
JPWO2020122034A5 true JPWO2020122034A5 (enExample) 2022-12-14
JP7608164B2 JP7608164B2 (ja) 2025-01-06

Family

ID=71076370

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020560106A Active JP7608164B2 (ja) 2018-12-11 2019-12-10 抗体-薬物コンジュゲートとparp阻害剤の組み合わせ
JP2024221344A Pending JP2025041725A (ja) 2018-12-11 2024-12-18 抗体-薬物コンジュゲートとparp阻害剤の組み合わせ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024221344A Pending JP2025041725A (ja) 2018-12-11 2024-12-18 抗体-薬物コンジュゲートとparp阻害剤の組み合わせ

Country Status (11)

Country Link
US (1) US20220023436A1 (enExample)
EP (1) EP3909580A4 (enExample)
JP (2) JP7608164B2 (enExample)
KR (1) KR20210102341A (enExample)
CN (1) CN113271942A (enExample)
AU (1) AU2019396895B2 (enExample)
BR (1) BR112021011119A2 (enExample)
EA (1) EA202191641A1 (enExample)
SG (1) SG11202106248XA (enExample)
TW (1) TW202034959A (enExample)
WO (1) WO2020122034A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3142119A1 (en) * 2019-05-29 2020-12-03 Daiichi Sankyo Company, Limited Dosage of an antibody-drug conjugate for treating cancer
EP4225314A1 (en) * 2020-10-09 2023-08-16 AstraZeneca UK Limited Combination of antibody-drug conjugate and parp1 selective inhibitor
WO2022248268A1 (en) * 2021-05-28 2022-12-01 Adc Therapeutics Sa Combination therapy
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
WO2023089527A1 (en) 2021-11-18 2023-05-25 Astrazeneca Uk Limited Combination of antibody-drug conjugate and parp1 selective inhibitor
CN119317447A (zh) 2022-04-12 2025-01-14 米纳瓦生物技术公司 抗可变muc1*抗体及其用途
EP4531927A1 (en) * 2022-05-24 2025-04-09 Daiichi Sankyo Company, Limited Dosage regimen of an anti-cdh6 antibody-drug conjugate
CN120813389A (zh) * 2023-03-14 2025-10-17 第一三共株式会社 抗cdh6抗体-药物缀合物和vegf抑制剂的组合
CN120916791A (zh) * 2023-03-31 2025-11-07 第一三共株式会社 抗CDH6抗体-药物缀合物与HIF-2α抑制剂的组合
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
EP4495003A1 (en) 2023-07-20 2025-01-22 AIRBUS HELICOPTERS DEUTSCHLAND GmbH An external cargo adapter for use with a rotorcraft
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
WO2000061739A1 (fr) 1999-04-09 2000-10-19 Kyowa Hakko Kogyo Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
PL203326B1 (pl) 1999-06-25 2009-09-30 Genentech Inc Przeciwciało, kompozycja farmaceutyczna, koniugat, izolowany kwas nukleinowy, wektor, komórka gospodarza i sposób wytwarzania przeciwciała
MXPA03002974A (es) 2000-10-06 2004-05-05 Kyowa Hakko Kogyo Kk Celulas que producen composiciones de anticuerpo.
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
CA2647632C (en) 2006-03-27 2017-06-27 University Of Maryland Biotechnology Institute Glycoprotein synthesis and remodeling by enzymatic transglycosylation
SI2716301T1 (sl) 2007-02-16 2017-07-31 Merrimack Pharmaceuticals, Inc. Protitelesa proti ErbB3 in uporaba le-teh
CN104220603B (zh) 2012-02-10 2017-06-06 马里兰大学,巴尔的摩 抗体及其Fc片段的化学酶法糖基化工程
KR102237639B1 (ko) 2012-10-11 2021-04-07 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트
ES2782248T3 (es) 2012-10-19 2020-09-11 Daiichi Sankyo Co Ltd Conjugado de anticuerpo y fármaco producido por la unión a través de un enlazador que tiene estructura hidrófila
IL320281A (en) * 2013-12-25 2025-06-01 Daiichi Sankyo Co Ltd Anti-trop2 antibodies and methods for producing same
PH12020552271A1 (en) * 2014-01-31 2022-05-02 Daiichi Sankyo Co Ltd Anti-her2 antibody-drug conjugate
JP2017114763A (ja) 2014-03-26 2017-06-29 第一三共株式会社 抗cd98抗体−薬物コンジュゲート
DK3129063T3 (da) 2014-04-10 2021-04-06 Daiichi Sankyo Co Ltd Anti-her3-antistof-lægemiddelkonjugat
EP3130608B1 (en) 2014-04-10 2019-09-04 Daiichi Sankyo Co., Ltd. (anti-her2 antibody)-drug conjugate
US10195175B2 (en) * 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
US11173213B2 (en) 2015-06-29 2021-11-16 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
EP3572428A4 (en) * 2017-01-17 2020-12-30 Daiichi Sankyo Company, Limited ANTI-BODY ANTI-GPR20 AND ANTI-BODY-DRUG CONJUGATE ANTI-GPR20
TW202530271A (zh) 2017-05-15 2025-08-01 日商第一三共股份有限公司 抗體-藥物結合物及其用途
KR20250084239A (ko) 2017-08-31 2025-06-10 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트의 개량 제조 방법

Similar Documents

Publication Publication Date Title
JPWO2020122034A5 (enExample)
JP2025041725A5 (enExample)
JPWO2020031936A5 (enExample)
JP2023070678A5 (enExample)
JPWO2020130125A5 (enExample)
JP2019031565A5 (enExample)
JPWO2020022475A5 (enExample)
JP2020509027A5 (enExample)
JP2010535713A5 (enExample)
JP2024075668A (ja) 抗体-薬物コンジュゲートとチューブリン阻害剤の組み合わせ
JP2015528818A5 (enExample)
JP2012522512A5 (enExample)
JP2012522513A5 (enExample)
HRP20171789T1 (hr) Konjugati humanog protutijela s lijekom protiv tkivnog faktora
NZ721213A (en) Anti-trop2 antibody-drug conjugate
JP2018525354A5 (enExample)
JPWO2020059772A5 (enExample)
JP2020515578A5 (enExample)
JP2015527318A5 (enExample)
IL311145B2 (en) Antibody drug conjugates (adc) that bind to 191p4d12 proteins
TWI838358B (zh) 疏水性奧瑞他汀(auristatin)f化合物及其結合物
JPWO2020259258A5 (enExample)
JP2020526584A5 (enExample)
JPWO2022102695A5 (enExample)
JP2020500834A5 (enExample)